Circulating VEGF Reduction, Response and Outcome in Advanced Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan

• Grothey A , SchmollHJ: New chemotherapy approaches in colorectal cancer.Curr. Opin. Oncol.13 , 275–286 (2001).
   PubMed Web of Science ®Google Scholar
• Venook A : Critical evaluation of current treatments in metastatic colorectal cancer.Oncologist10 , 250–261 (2005).
   PubMed Web of Science ®Google Scholar
• Baselga J : Why the epidermal growth factor receptor? The rationale for cancer therapy.Oncologist7 , S2–S8 (2002).
   PubMed Web of Science ®Google Scholar
• Salomon DS , BrandtR, CiardielloF, NormannoN: Epidermal growth factor-related peptides and their receptors in human malignancies.Crit. Rev. Oncol. Hematol.19 , 183–232 (1995).
   PubMed Web of Science ®Google Scholar
• Woodburn JR : The epidermal growth factor receptor and its inhibition in cancer therapy.Pharmacol. Ther.82 , 241–250 (1999).
   PubMed Web of Science ®Google Scholar
• Nicholson RI , GeeJM, HarperME: EGFR and cancer prognosis.Eur. J. Cancer37 , S9–S15 (2001).
   PubMed Web of Science ®Google Scholar
• Mendelsohn J , BaselgaJ: The EGF receptor family as targets for cancer therapy.Oncogene19 , 6550–6565 (2000).
   PubMed Web of Science ®Google Scholar
• Arteaga CL : Epidermal growth factor receptor dependence in human tumors: more than just expression.Oncologist7 , 31–39 (2002).
   PubMed Web of Science ®Google Scholar
• Peng D , FanZ, LuY et al.: Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res.56 , 3666–3669 (1996).
   PubMed Web of Science ®Google Scholar
• Vallbohmer D , LenzHJ: Epidermal growth factor receptor as a target for chemotherapy.Clin. Colorectal Cancer5 , S19–S27 (2005).
   PubMed Web of Science ®Google Scholar
• Perrotte P , MatsumotoT, InoueK et al.: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res.5 , 257–265 (1999).
   PubMed Web of Science ®Google Scholar
• Karashima T , SweeneyP, SlatonJW et al.: Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically innude mice. Clin. Cancer Res.8 , 1253–1264 (2002).
   PubMed Web of Science ®Google Scholar
• Mendelsohn J : Blockade of receptors for growth factors: an anticancer therapy – the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture.Clin. Cancer Res.6 , 747–753 (2000).
   PubMed Web of Science ®Google Scholar
• Milas L , FanZ, AndratschkeNH, AngKK: Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies.Int. J. Radiat. Oncol. Biol. Phys.58 , 966–971 (2004).
   PubMed Web of Science ®Google Scholar
• Bruns CJ , HarbisonMT, DavisDW et al.: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res.6 , 1936–1948 (2000).
   PubMed Web of Science ®Google Scholar
• Inoue K , SlatonJW, PerrotteP et al.: Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res.6 , 4874–4884 (2000)
   PubMed Web of Science ®Google Scholar
• Prewett MC , HooperAT, BassiR, EllisLM, WaksalHW, HicklinDJ: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.Clin. Cancer Res.8 , 994–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Vincenzi B , SantiniD, RussoA et al.: Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. Ann. Oncol.17 , 835–841 (2006).
   PubMed Web of Science ®Google Scholar
• Therasse P , ArbuckSG, EisenhauerEA et al.: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst.92 , 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Kaplan E , MeierP: Nonparametric estimation from incomplete observations.J. Am. Stat. Assoc.53 , 457–481 (1958).
   Web of Science ®Google Scholar
• Peto R , PikeMC, ArmitageP et al.: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br. J. Cancer35 , 1–39 (1977).
   PubMed Web of Science ®Google Scholar
• Cox DR : Regression models and life tables.J. R. Stat. Soc.34 , 187–220 (1972).
   Google Scholar
• Petit AM , RakJ, HungWC et al.: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol.151 , 1523–1530 (1997).
   PubMed Web of Science ®Google Scholar
• Masui H , KawamotoT, SatoJD et al.: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res.44 , 1002–1007 (1984).
   PubMed Web of Science ®Google Scholar
• Radinsky R , RisinS, FanD et al.: Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin. Cancer Res.1 , 19–31 (1995).
   PubMed Web of Science ®Google Scholar
• Dinney CPN , ParkerC, DongA et al.: Therapy of human transitional cell carcinoma of the bladder by oral administration of epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin. Cancer Res.3 , 161–168 (1997).
   PubMed Web of Science ®Google Scholar
• Fan Z , MasuiH, AtlasI, MendelsohnJ: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 of anti-epidermal growth factor receptor monoclonal antibodies.Cancer Res.53 , 4322–4238 (1993).
   PubMed Web of Science ®Google Scholar
• Kizaka-Kondoh S , SatoK, TamuraK, NojimaH, OkayamaH: Raf-1 protein kinase is an integral component of the oncogenic signal cascade shared by epidermal growth factor and platelet-derived growth factor.Mol. Cell. Biol.12 , 5078–5086 (1992).
   PubMed Web of Science ®Google Scholar
• Chung LW : Implications of stromal-epithelial interaction in human prostate cancer growth, progression and differentiation.Semin. Cancer Biol.4 , 183–192 (1993).
   PubMed Web of Science ®Google Scholar
• Zak DE , HaoH, VadigepalliR et al.: Systems analysis of circadian time-dependent neuronal epidermal growth factor receptor signaling. Genome Biol.7(6) , R48 (2006).
   PubMedGoogle Scholar
• Goldman CK , KimJ, WongWL et al.: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell4 , 121–133 (1993).
   PubMed Web of Science ®Google Scholar
• Akagi M , KawaguchiM, LiuW et al.: Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br. J. Cancer88 , 796–802 (2003).
   PubMed Web of Science ®Google Scholar
• Parikh AA , LiuWB, FanF et al.: Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer98 , 720–729 (2003).
   PubMed Web of Science ®Google Scholar
• Vallbohmer D , ZhangW, GordonM et al.: Molecular determinants of cetuximab efficacy. J. Clin. Oncol.23 , 3536–3544 (2005).
   PubMed Web of Science ®Google Scholar
• Tonra JR , DeeviDS, CorcoranE et al.: Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res.12 , 2197–2207 (2006).
   PubMed Web of Science ®Google Scholar
• Chung KY , ShiaJ, KemenyNE et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol.23(9) , 1803–1810 (2005).
   PubMed Web of Science ®Google Scholar
• Vincenzi B , SantiniD, ToniniG: New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.J. Clin. Oncol.24(12) , 1957 (2006).
   PubMed Web of Science ®Google Scholar
• Bocci G , ManS, GreenSK et al.: Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res.64(18) , 6616–6625 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham D , HumbletY, SienaS et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351 , 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Vincenzi B , SantiniD, RabittiC et al.: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre Phase II trial. Br. J. Cancer94 , 792–797 (2006).
   PubMed Web of Science ®Google Scholar
• Gebbia V , Del Prete S, Borsellino N et al.: Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin. Colorectal Cancer5(6) , 422–428 (2006).
   PubMed Web of Science ®Google Scholar
• George ML , EcclesSA, TuttonMG, Abulafi AM, Swift RI: Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin. Cancer Res.6 , 3147–3152 (2000).
   PubMed Web of Science ®Google Scholar
• Gunsilius E , PetzerA, StockhammerG et al.: Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology58 , 169–174 (2000).
   PubMed Web of Science ®Google Scholar

Website

• American Cancer Society: Cancer Facts and Figures. American Cancer Society, Atlanta, GA, USA (2005) www.cancer.org/downloads/STT/CAFF2005f4PWSecured.pdf
   Google Scholar